
UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))



Mail Stop Patent Application Commissioner for Patents

	O. Box 1 xandria,	450 VA 22313-1450	I here deposi Expres Patent Box 14	by certify that this correspondence is being ted with the United States Postal Service as as Mail in an envelope addressed to Mail Stop Application, Commissioner for Patents, P.O. Application, VA 22313-1450, on Service 3.				
		d herewith for filing is the patent application FR 1.53(b) of:	Signat	Date of Descrit Signature EL721892015US				
INV TIT TH	'ENTOR LE: AT DECI	OCKET NO.: USAV2002/0121USNP S: LI et al. METHOD FOR ASSAYING COMPOUNDS REASE THE ACTIVITY OF POLY(ADP- OLYMERASE (PARP)	·	s Mail No.				
APF	PLICATION	ON ELEMENTS						
1.		ee Transmittal Form (e.g., PTO/SB/17) Submit an original and a duplicate for fee processing)						
2.	(p - [- (- S - F - E - E - E	pecification referred arrangement set forth below) Descriptive title of the Invention Cross References to Related Applications Statement Regarding Fed sponsored R & D Reference to Microfiche Appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure	Total Pages	25				
3.	D D	rawing(s) (35 U.S.C. 113)	Total Sheet	s 6				
4.	Oath or a.	Declaration Unexecuted (original or copy)	Total Pages	2				
b. Copy from a prior application (37 CFR § 1.63(d))								
	i.	DELETION OF INVENTOR(S) Signed statement attached deleting is application, see 37 CFR §§ 1.63(d)(2)	nventor(s) na 2) and 1.33(b	amed in the prior				
5.	Power of	of Attorney Newly executed (original or copy)	Total Pages	1				
	b. [Copy from a prior application (37 CFR § 1.	63(d))	·				
6.	Mi	crofiche Computer Program (Appendix)						

Application Transmittal Letter Page 2 •									
Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies									
If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no:, filed, Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).									
This application claims the benefit of U.S. Provisional Application No. 60/412,136, filed September 19, 2002 and claims priority to the Great Britain Application No. 0301628.4 filed January 24, 2003. (The cross reference has been/will be inserted on page one of the specification).									
Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
ACCOMPANYING APPLICATION PARTS									
7. Assignment Papers (cover sheet & document(s))									
8. 37 CFR §3.73(b) Statement									
(when there is an assignee)									
9.									
10 Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449									
11. Preliminary Amendment									
12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)									
13. Statement filed in prior application,									
14. Certified Copy of Priority Document(s)									
(if foreign priority is claimed) 15. Other: Application Data Sheet									
CORRESPONDENCE ADDRESS									
Customer Number or Bar Code Label 005487									
(Insert Customer No. or Attach bar code label here)									
William C. Coppola, Reg. No. 41,686									

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3800

To Be Assigned

Herewith

02527 U.S. 09/18/03

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Application Number

Filing Date

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

First Named Inventor

Examiner Name

To Be Assigned

Group / Art Unit

Unknown

Applicant claims small entity status. See 37 CFR 1.27 Group / Art Unit Unknown

TOTAL AMOUNT OF PAYMENT (\$) 924.00 Attorney Docket No. USAV2002/0121USNP

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)								
Check Credit Card Money Other None Order	3. ADDITIONAL FEES								
Deposit Account	Large E	ntity	Small E	ntity					
Deposit Account Number 18-1982	Fee Code	Fee (\$)	Fee Code	Fee (\$)		_			
Deposit Account Aventis Pharmaceuticals Inc.					Fee Description	Fee Paid			
Name	1051	130	2051	65	Surcharge - late filing fee or oath				
The Commissioner is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet				
Charge any additional fee(s) during the pendency of this application	1053	130	1053	130	Non-English Specification				
Charge fee(s) indicated below, except for the filing fee	1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination Requesting publication of SIR prior to				
to the above-identified deposit account					Examiner action				
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action				
1. BASIC FILING FEE Large Entity Small Entity Fee	1251	110	2251	55	Extension for reply within first month				
Fee Fee Fee Fee Description Paid Code (\$) Code (\$)	1252	410	2252	205	Extension for reply within second month				
1001 750 2001 375 Utility filing fee 750	1253	930	2253	465	Extension for reply within third month				
1002 330 2002 165 Design filing Fee	1254	1,450	2254	725	Extension for reply within fourth month	,			
1003 520 2003 260 Plant filing fee 1004 750 2004 375 Reissue filing fee	1255	1970	2255	985	Extension for reply within fifth month				
1004 750 2004 375 Reissue filing fee 1005 160 2005 80 Provisional filing fee	1401	320	2401	160	Notice of Appeal				
	1402 1403	320 280	2402 2403	160 140	Filing a brief in support of an appeal				
SUBTOTAL (1) (\$)750.00		i			Request for oral hearing				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding				
Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable				
Claims below Paid Total Claims 25 -20**= 5 x 18 = 90	1450	4 200	0450	050					
	1453	1,300	2453	650	Petition to revive - unintentional				
Independent 4 - 3**= 1 x 84 = 84	1501	1,300	2501	650	Utility issue fee (or reissue)				
Claims Multiple Dependent	1502 1503	470 630	2502 2503	235	Design issue fee				
Multiple Dependent =	1460	130	1460	315 130	Plant issue fee				
Large Entity Small Entity	1807	50	1807	50	Petitions to the Commissioner Petitions related to provisional				
Fee Fee Fee Code (\$) Fee Description					applications				
1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure Stmt				
1201 84 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per				
1203 280 2203 140 Multiple dependent claim, if not paid	1809	750	2809	375	property (times number of properties) Filing a submission after final rejection (37 CFR § 1.129(a))				
1204 84 2204 42 **Reissue independent	1810	750	2810	375	For each additional invention to be				
claims over original patent 1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	750	2801	375	examined (37 CFR § 1.129(b)) Request for Continued Examination				
1 20 and over original patent	1802	900	1802	900	(RCE) Request for expedited examination of a				
SUBTOTAL (2) (\$)174.00	Other fee	(specify)	***************************************	********	design application				
**or number previously paid, if greater; For Reissues, see above	*Reduced	l by Basic	Filing Fee	Paid	SUBTOTAL (3) (\$)				
SUBMITTED BY Complete (If applicable)									

Name (Print/Type) William C. Coppola Registration No. (Attorney/Agent) 41,686 Telephone (908) 231-3800
Signature Date 7//8/03

WARNING: Inf rmation on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorizati n on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.